Get started
Author

Vincent Haddad

Observed names: Haddad, Vincent, V. Haddad
Observed institutions: AstraZeneca (United Kingdom), Inserm, Université Joseph Fourier, Chinese University of Hong Kong, Medical University of Graz, University of Zurich, Sichuan University, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Guangdong General Hospital, Centre Hospitalier Universitaire de Grenoble, Melbourn Science Park, Institut Gustave Roussy, Peking University Cancer Hospital, CEA Paris-Saclay - Etablissement de Fontenay-aux-roses, University Hospital Zurich, Prince of Wales Hospital, Amgen (United Kingdom), Guangdong Academy of Medical Sciences, AstraZeneca (United States), Hôpital Albert Michallon, Medical University of Vienna, Institut Curie
ORCID: 0000-0001-8290-2443
Observed ORCID: 0000-0001-8290-2443
OpenAlex ID: A5103129530
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
2006 · Ken A. Olaussen, Ariane Dunant, et al. · New England Journal of Medicine · 1,727
PDF
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
2018 · Nicola Gökbuget, Hervé Dombret, et al. · Blood · 860
PDF
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients
2007 · S. Bonvalot, H. Eldweny, et al. · European Journal of Surgical Oncology · 277
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
2017 · Tony S.K. Mok, Sang-We Kim, et al. · Journal of Clinical Oncology · 180
Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
2009 · Karim Fizazi, Philippe Beuzeboc, et al. · Journal of Clinical Oncology · 173
PDF
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
2015 · C.S. Fuchs, S. Azevedo, et al. · Annals of Oncology · 168
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
2017 · Monique B. Nilsson, Huiying Sun, et al. · Science Translational Medicine · 146
Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program
2007 · Martin Filipits, Robert Pirker, et al. · Journal of Clinical Oncology · 116
PDF
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
2017 · Tina Cascone, Li Xu, et al. · Clinical Cancer Research · 87
Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program
2007 · Martin Filipits, Vincent Haddad, et al. · Clinical Cancer Research · 81
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2013 · Luis Paz-Ares, Beatrix Bálint, et al. · Journal of Thoracic Oncology · 74
PDF
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer
2023 · Aditya Bardia, Komal Jhaveri, et al. · Future Oncology · 73
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer
2013 · Charles S. Fuchs, Marwan Fakih, et al. · Cancer · 66
PDF
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)
2014 · Nicola Goekbuget, Hervé Dombret, et al. · Blood · 60
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
2016 · Yi-Long Wu, Nagahiro Saijo, et al. · Lung Cancer · 56
Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
2015 · Nicola Gökbuget, Hervé Dombret, et al. · Blood · 53
Importance of Contact Surface between Electrodes and Treated Tissue in Electrochemotherapy
2008 · Selma Čorović, Bassim Al Sakere, et al. · Technology in Cancer Research & Treatment · 41
OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
2017 · M. Ahn, J. Han, et al. · Journal of Thoracic Oncology · 35
PDF
Estimands for overall survival in clinical trials with treatment switching in oncology
2021 · Juliane Manitz, Natalia Kan‐Dobrosky, et al. · Pharmaceutical Statistics · 33
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
2021 · Seock-Ah Im, Erika P. Hamilton, et al. · Journal of Clinical Oncology · 30
Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice
2009 · Christophe Massard, Pierre Tran Ba Loc, et al. · Journal of Thoracic Oncology · 16
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
2020 · Peter Schmid, Javier Cortes, et al. · Journal of Clinical Oncology · 15
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
2010 · B. Besse, C. Massard, et al. · Annals of Oncology · 15
Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.
2010 · S. P. Chawla, J. Tabernero, et al. · Journal of Clinical Oncology · 14
Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies.
2011 · Y. Pan, V. Haddad, et al. · Journal of Clinical Oncology · 12
Works count: 51
Citation count: 4,485
H-index: 20
I10-index: 27
Year
Topic
Type